Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amylyx Pharmaceuticals Inc AMLX

Healthcare
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral... see more

Recent & Breaking News (NDAQ:AMLX)

Lifshitz Law PLLC Announces Investigations of Meta Platforms, Inc. (NASDAQ: META), Amplitude, Inc. (NASDAQ: AMPL), ON Semiconductor Corporation (NASDAQ: ON), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

Accesswire 8 days ago

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Business Wire April 10, 2024

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Newsfile April 9, 2024

April 9, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AMLX

Accesswire April 9, 2024

AMLX DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Alerts Amylyx Pharmaceuticals (AMLX) Investors to Today's Lead Plaintiff Deadline in Securities Fraud Class Action

Accesswire April 9, 2024

Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire April 9, 2024

Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire April 9, 2024

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire April 9, 2024

The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX

PR Newswire April 9, 2024

Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire April 9, 2024

AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile April 9, 2024

FINAL AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!

Accesswire April 9, 2024

Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire April 8, 2024

AMYLYX PHARMACEUTICALS 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

Accesswire April 8, 2024

AMLX FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action

Newsfile April 8, 2024

48 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Newsfile April 8, 2024

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)

Business Wire April 8, 2024

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX

Accesswire April 8, 2024

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

Business Wire April 8, 2024

Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire April 8, 2024